Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 21% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-05-03. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patienttherapypatientsevidence ofct
  Phrases that lowered it: evaluate theto evaluateinvestigator20clinical
• Sponsor's past termination rate: 12.8% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 43.7% (raises risk) · Drug's FDA history
• Phase: 2 (raises risk) · Design
• Design: parallel (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 96.3% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 47 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 219 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Milrinone Infusion for VAsospam Treatment in Subarachnoid hemoRrhage NCT04362527 · started 2020 · scored riskier than 95% of active trials completed
• Management of Cerebral Vascular Spasm in Posttraumatic Subarachnoid Hemorrhage Using Combination Therapy NCT05131867 · started 2021 · scored riskier than 14% of active trials completed
• Effects of Prostacyclin Infusion on Cerebral Vessels and Metabolism in Patients With Subarachnoid Haemorrhage NCT01447095 · started 2011 · scored riskier than 63% of active trials completed
• Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage NCT02560532 · started 2016 · scored riskier than 96% of active trials completed
• Poststroke Depression in Hemorrhagic Stroke NCT03826875 · started 2019 · scored riskier than 30% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.